Mode
Text Size
Log in / Sign up
N/A N=150

Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis

Skin Diseases

Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: True Positive — 0 samples

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
U.S. Army Medical Research and Development Command
Primary completion
Aug 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
True Positive
PRIMARY
False Positive
6
PRIMARY
True Negative
144
PRIMARY
False Negative
PRIMARY
Specificity
96.0
PRIMARY
False Positive Rate
4.0

Summary

This study is a single-site trial assessing the specificity of CL Detect™ Rapid Test versus the gold standard for Leishmania diagnosis in the US which is microscopic identification of Leishmania amastigotes in a stained lesion sample.

Eligibility Criteria

Inclusion Criteria

  • At least 18 years of age
  • Subject is able to give written informed consent
  • Subject has a skin ulcer that satisfies the following criteria for an index lesion:
  • less than 4 months in age
  • primarily ulcerative, not purely verrucous or nodular, and does not have clear clinical evidence of cellulitis
  • in a location suitable for collecting samples by dental broach and scraping
  • In the opinion of the investigator, the subject is capable of understanding and complying with the protocol

Exclusion Criteria

  • Received treatment for leishmaniasis or any treatment to the lesion even if not previously diagnosed as leishmaniasis such as azoles, cryotherapy, imiquimod, thermotherapy, photodynamic therapy, within 2 months prior to signing the consent form, with the exception of mercurochrome
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01865032). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search